Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia.
Severe persistent pulmonary hypertension of the newborn (PPHN) remains a significant cause of neonatal morbidity and mortality with limited effective treatment options. We present the first case of a neonate with PPHN treated concurrently with inhaled nitric oxide (iNO) and intravenous prostacyclin (PGI2). He ultimately was diagnosed with alveolar-capillary dysplasia, a rare and fatal cause of pulmonary hypertension. However, his partial response to treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with severe PPHN.
Parker
T A
TA
Department of Pediatrics, University of Colorado School of Medicine, The Children's Hospital, Denver, USA.
Ivy
D D
DD
Kinsella
J P
JP
Torielli
F
F
Ruyle
S Z
SZ
Thilo
E H
EH
Abman
S H
SH
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004452:Echocardiography; D011464:Epoprostenol / Q000008:administration & dosage*; D017809:Fatal Outcome; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage*; D011651:Pulmonary Artery / Q000002:abnormalities; D011667:Pulmonary Veins / Q000002:abnormalities
D000959:Antihypertensive Agents; D009569:Nitric Oxide; D011464:Epoprostenol